Form 4: Bristol-Myers Squibb Director Acquires DSUs

A director at Bristol-Myers Squibb Company acquired 926.956 Deferred Share Units as part of a compensation plan.

Summary

• Theodore R. Samuels II, a Director of Bristol-Myers Squibb Company (BMY), acquired 926.956 Deferred Share Units (DSUs).
• This acquisition occurred on December 31, 2025.
• Each DSU is convertible into one share of BMY common stock upon settlement.
• Settlement occurs when Mr. Samuels ceases to be a director or at a previously specified future date.
• The acquisition is part of deferred compensation and includes dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Following this transaction, Mr. Samuels beneficially owns 63,174.032 Deferred Share Units.

Sentiment

Score: 6

Explanation: The filing reports a routine acquisition of Deferred Share Units by a director as part of a compensation plan, which is a neutral to slightly positive event indicating continued alignment of interests.

Positives

• The acquisition of Deferred Share Units by a director indicates continued alignment of interests between management and shareholders.
• The DSUs are part of a deferred compensation plan, suggesting a structured approach to director remuneration.

Negatives

• No specific negative points are identified in this filing, as it reports a routine compensation-related acquisition.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The Deferred Share Units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified. This indicates a future conversion event.

Industry Context

The acquisition of Deferred Share Units is a common form of equity compensation for non-employee directors in publicly traded companies, aligning their long-term interests with those of shareholders. This practice is standard across various industries, including pharmaceuticals.

Comparison to Industry Standards

• The use of Deferred Share Units as a component of non-employee director compensation is a widely accepted practice in corporate governance, aligning director incentives with long-term shareholder value.
• Many large pharmaceutical companies, similar to Bristol-Myers Squibb, utilize similar equity-based compensation structures for their board members.

Corporate Governance

Related Party Transactions

• The acquisition of Deferred Share Units by a director as part of a compensation plan can be considered a related party transaction, as it involves a transaction between the company and a member of its board.

Stakeholder Impact

• Shareholders: The acquisition of DSUs by a director aligns the director's long-term interests with those of shareholders, potentially fostering better governance and strategic decisions aimed at increasing share value.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.

Next Steps

• The Deferred Share Units will convert into common stock upon the director ceasing to be a director or at a specified future date.

Key Dates

Recommendation

This Form 4 filing reports a routine director compensation event involving the acquisition of Deferred Share Units. It does not contain information that would significantly alter the fundamental investment thesis for Bristol-Myers Squibb. While it shows continued alignment of director interests, it's not a catalyst for a "buy" or "sell" recommendation. Therefore, a "hold" recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions.

Keywords

Bristol-Myers Squibb, BMY, Deferred Share Units, DSU, Director compensation, Insider transaction, SEC Form 4, Beneficial ownership, Equity compensation